How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark

Peter Polzik, Pär I Johansson, Ole Hyldegaard, Peter Polzik, Pär I Johansson, Ole Hyldegaard

Abstract

Introduction: Not enough is known regarding the prognosis and treatment of necrotising soft tissue infections (NSTIs). Mortality has been shown to be 25%-35%, with survivors coping with amputations and prolonged rehabilitation. This study will evaluate soluble urokinase-type plasminogen activator receptor (suPAR) as a possible prognostic marker of NSTI severity and mortality, as well as whether hyperbaric oxygen therapy (HBOT) can modulate markers of endothelial damage during NSTI. We hypothesise that in patients with NSTI, suPAR can provide prognostic risk assessment on hospital admission and that HBOT can reduce the endothelial damage that these patients are exposed to.

Methods and analysis: This is a prospective observational study. Biomarkers will be measured in 150 patients who have been diagnosed with NSTI. On admission, baseline blood samples will be obtained. Following surgery and HBOT, daily blood samples will be obtained in order to measure endothelial and prognostic biomarkers (soluble thrombomodulin, syndecan-1, sE-selectin, vascular endothelial (VE)-cadherin, protein C and suPAR levels). Clinical data will be acquired during the first 7 days of stay in the intensive care unit. The primary outcomes in studies I and II will be endothelial biomarker levels after HBOT, and in study III suPAR levels as a marker of disease prognosis and severity.

Ethics and dissemination: The study has been approved by the Regional Scientific Ethical Committee of Copenhagen (H-16021845) and the Danish Data Protection Agency (RH-2016-199). Results will be presented at national and international conferences and published in peer-reviewed scientific journals.

Trial registration number: ClinicalTrials.gov Identifier NCT03147352. (Pre-results).

Keywords: infectious diseases; intensive care; surgery.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

    1. Hakkarainen TW, Kopari NM, Pham TN, et al. . Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Probl Surg 2014;51:344–62. 10.1067/j.cpsurg.2014.06.001
    1. Shaw JJ, Psoinos C, Emhoff TA, et al. . Not just full of hot air: hyperbaric oxygen therapy increases survival in cases of necrotizing soft tissue infections. Surg Infect 2014;15:328–35. 10.1089/sur.2012.135
    1. Soh CR, Pietrobon R, Freiberger JJ, et al. . Hyperbaric oxygen therapy in necrotising soft tissue infections: a study of patients in the United States Nationwide Inpatient Sample. Intensive Care Med 2012;38:1143–51. 10.1007/s00134-012-2558-4
    1. Devaney B, Frawley G, Frawley L, et al. . Necrotising soft tissue infections: the effect of hyperbaric oxygen on mortality. Anaesth Intensive Care 2015;43:685–92.
    1. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009;27:157–72. 10.1155/2009/504294
    1. Reitsma S, et al. . The endothelial glycocalyx. Pflugers Arch 2007;454:345–59.
    1. Jallali N, Withey S, Butler PE, et al. . Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg 2005;189:462–6. 10.1016/j.amjsurg.2005.01.012
    1. van den Berg BM, Vink H, Spaan JA, et al. . The endothelial glycocalyx protects against myocardial edema. Circ Res 2003;92:592–4. 10.1161/01.RES.0000065917.53950.75
    1. De Backer D, Donadello K, Favory R, et al. . Link between coagulation abnormalities and microcirculatory dysfunction in critically ill patients. Curr Opin Anaesthesiol 2009;22:150–4. 10.1097/ACO.0b013e328328d1a1
    1. Ostrowski SR, Gaïni S, Pedersen C, et al. . Sympathoadrenal activation and endothelial damage in patients with varying degrees of acute infectious disease: an observational study. J Crit Care 2015;30:90–6. 10.1016/j.jcrc.2014.10.006
    1. Johansen ME, Jensen JU, Bestle MH, et al. . The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. PLoS One 2013;8:e81477 10.1371/journal.pone.0081477
    1. Ostrowski SR, Berg RM, Windeløv NA, et al. . Coagulopathy, catecholamines, and biomarkers of endothelial damage in experimental human endotoxemia and in patients with severe sepsis: a prospective study. J Crit Care 2013;28:586–96. 10.1016/j.jcrc.2013.04.010
    1. Johansson PI, Stensballe J, Rasmussen LS, et al. . A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011;254:194–200. 10.1097/SLA.0b013e318226113d
    1. Ostrowski SR, Pedersen SH, Jensen JS, et al. . Acute myocardial infarction is associated with endothelial glycocalyx and cell damage and a parallel increase in circulating catecholamines. Crit Care 2013;17:R32 10.1186/cc12532
    1. Johansson PI, Bro-Jeppesen J, Kjaergaard J, et al. . Sympathoadrenal activation and endothelial damage are inter correlated and predict increased mortality in patients resuscitated after out-of-hospital cardiac arrest. a post Hoc sub-study of patients from the TTM-trial. PLoS One 2015;10:e0120914 10.1371/journal.pone.0120914
    1. Rehm M, Bruegger D, Christ F, et al. . Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation 2007;116:1896–906. 10.1161/CIRCULATIONAHA.106.684852
    1. Blann A, Seigneur M. Soluble markers of endothelial cell function. Clin Hemorheol Microcirc 1997;17:3–11.
    1. Johansson PI, Sørensen AM, Perner A, et al. . High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality. J Thromb Haemost 2012;10:207–16. 10.1111/j.1538-7836.2011.04589.x
    1. Lin HC, Wan FJ, Wu CC, et al. . Hyperbaric oxygen protects against lipopolysaccharide-stimulated oxidative stress and mortality in rats. Eur J Pharmacol 2005;508:249–54. 10.1016/j.ejphar.2004.12.021
    1. Imperatore F, Cuzzocrea S, De Lucia D, et al. . Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome. Intensive Care Med 2006;32:1881–8. 10.1007/s00134-006-0367-3
    1. Cuzzocrea S, Imperatore F, Costantino G, et al. . Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat. Shock 2000;13:197–203. 10.1097/00024382-200003000-00005
    1. Pedoto A, Nandi J, Yang ZJ, et al. . Beneficial effect of hyperbaric oxygen pretreatment on lipopolysaccharide-induced shock in rats. Clin Exp Pharmacol Physiol 2003;30:482–8. 10.1046/j.1440-1681.2003.03865.x
    1. Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 2011;127(Suppl 1):131S–41. 10.1097/PRS.0b013e3181fbe2bf
    1. Thom SR. Oxidative stress is fundamental to hyperbaric oxygen therapy. J Appl Physiol 2009;106:988–95. 10.1152/japplphysiol.91004.2008
    1. Mader JT, Brown GL, Guckian JC, et al. . A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis 1980;142:915–22. 10.1093/infdis/142.6.915
    1. Kalns J, Lane J, Delgado A, et al. . Hyperbaric oxygen exposure temporarily reduces Mac-1 mediated functions of human neutrophils. Immunol Lett 2002;83:125–31. 10.1016/S0165-2478(02)00068-8
    1. Chen Q, et al. . Functional inhibition of leukocyte B2 integrins by HBO. J. Pharmacol. Exp. Ther 1996;276:929–33.
    1. Thom SR. Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol 1993;123:248–56. 10.1006/taap.1993.1243
    1. Buras JA, Stahl GL, Svoboda KK, et al. . Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell Physiol 2000;278:C292–302.
    1. Zamboni WA, Roth AC, Russell RC, et al. . Morphologic analysis of the microcirculation during reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen. Plast Reconstr Surg 1993;91:1110–23. 10.1097/00006534-199305000-00022
    1. Giannotta M, Trani M, Dejana E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev Cell 2013;26:441–54. 10.1016/j.devcel.2013.08.020
    1. Hunt BJ, Jurd KM. A central pathophysiological process. BMJ 1998;316:1328 10.1136/bmj.316.7141.1328
    1. Chong AY, Blann AD, Lip GY. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM 2003;96:253–67. 10.1093/qjmed/hcg037
    1. Gavard J. Endothelial permeability and VE-cadherin: a wacky comradeship. Cell Adh Migr 2014;8:158–64.
    1. Godman CA, Chheda KP, Hightower LE, et al. . Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. Cell Stress Chaperones 2010;15:431–42. 10.1007/s12192-009-0159-0
    1. Eugen-Olsen J, Andersen O, Linneberg A, et al. . Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010;268:296–308. 10.1111/j.1365-2796.2010.02252.x
    1. Lyngbæk S, Marott JL, Sehestedt T, et al. . Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int J Cardiol 2013;167:2904–11. 10.1016/j.ijcard.2012.07.018
    1. Gumus A, Altintas N, Cinarka H, et al. . Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Int J Chron Obstruct Pulmon Dis 2015;10:357–65. 10.2147/COPD.S77654
    1. Mölkänen T, Ruotsalainen E, Thorball CW, et al. . Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2011;30:1417–24. 10.1007/s10096-011-1236-8
    1. Wittenhagen P, Kronborg G, Weis N, et al. . The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004;10:409–15. 10.1111/j.1469-0691.2004.00850.x
    1. Huttunen R, Syrjänen J, Vuento R, et al. . Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011;270:32–40. 10.1111/j.1365-2796.2011.02363.x
    1. Ostergaard C, Benfield T, Lundgren JD, et al. . Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004;36:14–19. 10.1080/00365540310017366
    1. Kofoed K, Eugen-Olsen J, Petersen J, et al. . Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008;27:375–83. 10.1007/s10096-007-0447-5
    1. Backes Y, van der Sluijs KF, Mackie DP, et al. . Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012;38:1418–28. 10.1007/s00134-012-2613-1
    1. Singer M, Deutschman CS, Seymour CW, et al. . The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10. 10.1001/jama.2016.0287
    1. Kayal S, Jaïs JP, Aguini N, et al. . Elevated circulating E-selectin, intercellular adhesion molecule 1, and von willebrand factor in patients with severe infection. Am J Respir Crit Care Med 1998;157:776–84. 10.1164/ajrccm.157.3.9705034

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa